Company: CMND
Filing Date: 2025-11-13
Form Type: 6-K
Source: 0001213900-25-109569
Chunk: 2

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-13
Form: 6-K
Chunk 2
---
 Statements

This Report of on Form 6-K contains statements which constitute forward
looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward
looking statements are based upon the Company’s present intent, beliefs or expectations, but forward looking statements are not
guaranteed to occur and may not occur for various reasons, including some reasons which are beyond the Company’s control. For example,
this Report states that the Offering is expected to close on or about November 14, 2025. In fact, the closing of the Offering is subject
to various conditions and contingencies as are customary in securities purchase agreements in the United States. If these conditions
are not satisfied or the specified contingencies do not occur, this Offering may not close. For this reason, among others, you should
not place undue reliance upon the Company’s forward looking statements. Except as required by law, the Company undertakes no obligation
to revise or update any forward looking statements in order to reflect any event or circumstance that may arise after the date of this
Report on Form 6-K.

<div align='center'>1

EXHIBIT INDEX</div>

| Exhibit No. |     |                                                                 |
| 5.1         |     | Opinion of Daniel N. Bloch, Canadian counsel to the Company     |
| 5.2         |     | Opinion of Greenberg Traurig, P.A., U.S. counsel to the Company |
| 10.1        |     | Form of Securities Purchase Agreement                           |
| 10.2        |     | Form of Pre-Funded Warrant                                      |
| 23.1        |     | Consent of Daniel N. Bloch (included in Exhibit 5.1)            |
| 23.2        |     | Consent of Greenberg Traurig, P.A. (included in Exhibit 5.2)    |

<div align='center'>2

SIGNATURES</div>

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.

| Date: November 13, 2025 | Clearmind Medicine, Inc. 
 (Registrant)             
 By:                      | /s/ Adi                 
 Zuloff-Shani            |
|:------------------------|:-------------------------|:------------------------|
|                         | Name: